 SAN DIEGO, Dec. 14, 2020 GLOBE NEWSWIRE -- Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the closing of its previously announced public offering on a firm commitment basis of 19,161,667 shares of common stock of the Company, including the exercise in full by the underwriter of its option to purchase an additional 2,495,000 shares of common stock, at a price to the public of 4.50 per share, less underwriting discounts and commissions. 